Higher buprenorphine doses help patients stay in opioid use disorder treatment, new study finds - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Health/Employee Benefits News
Newswires RSS Get our newsletter
Order Prints
March 10, 2026 Newswires
Share
Share
Post
Email

Higher buprenorphine doses help patients stay in opioid use disorder treatment, new study finds

Rachel French, Assistant Professor of Family and Community Health, University of PennsylvaniaThe Conversation

Patients who are prescribed higher daily doses of the medication buprenorphine for opioid use disorder are significantly more likely to stay in treatment. Those on 17 to 24 milligrams averaged 190 days in care compared to 90 days for those on 8 milligrams or less. Yet Black patients are less likely than white patients to receive the higher doses.

Those are the key findings of a study my colleagues and I conducted with 5,000 adults enrolled in Medicaid in Philadelphia who are prescribed buprenorphine to treat their opioid use disorder.

I am an assistant professor at University of Pennsylvania’s School of Nursing, and my research focuses on improving care and outcomes for people with opioid use disorder.

Why it matters

Buprenorphine is one of the most effective treatments for opioid use disorder. Unlike most opioids, buprenorphine only partially activates opioid receptors, providing enough stimulation to prevent withdrawal and cravings while not causing euphoria. This lowers the risk of overdose.

Buprenorphine also blocks other opioids from binding to opioid receptors and causing euphoric effects. This deters patients from using other opioids while on the medication.

Across the board, patients who received higher doses of buprenorphine – usually 17 to 24 milligrams per day, but sometimes more – stayed in treatment significantly longer than those who started on medium doses of 9 to 16 milligrams, or lower doses of 8 milligrams.

Staying in treatment for opioid use disorder is important because it reduces overdose risk and provides a foundation for recovery.

Our study also revealed racial disparities.

Black patients were less likely than white patients to receive the 17 to 24 milligram prescriptions. These differences may reflect prescriber preferences, inequities in health care or misconceptions among both patients and clinicians about safe dosing.

Other groups were more likely to receive higher buprenorphine doses. Over half of our sample was diagnosed with a musculoskeletal condition – such as osteoarthritis, rheumatoid arthritis and gout – alongside opioid use disorder. These patients were more likely to receive higher doses.

Why it matters

Over the past decade, the unregulated street opioid supply across the U.S. – and notably in Philadelphia – has become much more potent and unpredictable. The powerful synthetic opioid fentanyl as well as the animal tranquilizers xylazine and medetomidine are pervasive in Philadelphia. With these changes, standard buprenorphine doses may not be enough to stabilize withdrawal symptoms and prevent patients from using again.

Identifying disparities in buprenorphine dosing also sets up a number of interventions that insurers can use to address them.

For example, Community Behavioral Health, Philadelphia’s Medicaid behavioral health managed-care organization, has provided education about buprenorphine at faith‑based conferences, convened focus groups with Medicaid members to understand barriers to buprenorphine treatment, and allowed us to present our findings in a forum with local prescribers and pharmacists.

In December 2024, the U.S. Food and Drug Administration updated its recommendations about buprenorphine dosing. Previously, it supported a target dose of 16 milligrams and said that doses over 24 milligrams showed no clinical advantage.

Now, the FDA has removed the phrase “target dose” from the drug label. It also added that although doses over 24 milligrams have not been investigated in randomized clinical trials, they “may be appropriate for some patients.”

This clarification rolls back outdated language that many clinicians and insurers took to mean that 16 milligrams was the maximum for treating opioid use disorder.

What still isn’t known

Clinicians still do not fully understand patient preferences around buprenorphine dosing. Some patients may want higher doses to better manage withdrawal or cravings. Others may prefer lower doses due to concerns about not being able to discontinue buprenophrine if they are on a high dose.

The dosing patterns that we observed suggest that Black patients do not have equal access to higher doses of buprenorphine they may need. Understanding why these differences occur, and how to address them, is essential to equitable treatment.

The Research Brief is a short take on interesting academic work.

Read more of our stories about Philadelphia and Pennsylvania, or sign up for our Philadelphia newsletter on Substack.

Rachel French does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Older

Rush Co. with lowest storm damage payout in Kansas in 2025

Newer

New Data from University of Minnesota Illuminate Findings in Investment (Central Bank Reputation With Noise): Investment

Advisor News

  • NAIFA applauds final SECURE 2.0 regulations
  • What will Democrats in Congress do about healthcare and retirement?
  • Election results cloud retirement legislation outlook, experts say
  • Planning for the missing chapter
  • Semi-retirement: helping clients balance flexibility with financial security
More Advisor News

Annuity News

  • ‘It’s really shocking:’ Regulators scrutinize assets backing annuity sellers
  • Jackson Launches Direct-to-Consumer Annuity Offering
  • Global Atlantic launches ForeIncome Flex
  • Athene CEO criticizes offshore reinsurance, risk-taking by competitors
  • DOL, trade groups, state AGs file briefs supporting Alcoa in PRT lawsuit
More Annuity News

Health/Employee Benefits News

  • Medicaid work rules don’t apply to Native Americans. They could still lose coverage.
  • Oscar Highlights Tailored New Health Products in Florida for 2027 Open Enrollment
  • Oscar Highlights Tailored New Health Products in Texas for 2027 Open Enrollment
  • States get until July to cut Medicaid coverage over work requirement
  • CRUSH Rule could crush health insurance agents, industry group says
More Health/Employee Benefits News

Life Insurance News

  • Best’s Commentary: Shanghai Cross-Border Investment Pilot Unlocks Overseas Growth Potential of China Non-Life Companies
  • Military Briefs: November 19-25
  • California’s new solvency rules: What should life insurance advisors watch?
  • Navigating delayed death certificates: A guide for life insurance advisors
  • Jackson Launches Direct-to-Consumer Annuity Offering
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Press Releases

  • OpenRoad Insurance Data Shows 40% of Collector Vehicles Are Model Year 1980 or Newer
  • Insurvoice Lets Independent Insurance Agency Owners Analyze Every Customer Call in ChatGPT or Claude
  • Spectrum Weather & Specialty Insurance Celebrates 15 Years and Welcomes the Next Generation
  • Royal Neighbors of America® Increases Service Capacity
  • Benefits Studio Launches to Fill the Missing Middle of Benefits Navigation at $49/mo
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.